Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Revolution Medicines, Inc. (RVMD)
|
Add to portfolio |
|
|
|
| Price: |
$24.88
| | Metrics |
| OS: |
109.2
|
M
| |
|
|
| Market cap: |
$2.72
|
B
| |
|
|
|
Net cash:
|
$380
|
M
| |
$3.48
|
per share
|
|
EV:
|
$2.34
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 35.4 | 35.4 | 29.4 | 29.4 | 43.0 | 50.0 | 20.2 | 26.6 |
| Revenue growth | 20.4% | 20.4% | -31.6% | | -14.1% | 148.2% | -24.2% | |
| Cost of goods sold | 0.0 | 293.7 | 0.0 | 217.4 | 0.0 | 0.0 | 0.0 | 31.1 |
| Gross profit | 35.4 | -258.3 | 29.4 | -188.0 | 43.0 | 50.0 | 20.2 | -4.5 |
| Gross margin | 100.0% | -730.0% | 100.0% | -639.7% | 100.0% | 100.0% | 100.0% | -17.1% |
| Selling, general and administrative | 293.7 | | 217.4 | | 153.7 | 104.2 | | |
| Research and development | | | | | | | 51.1 | |
| General and administrative | | 40.6 | | 30.5 | | | 9.4 | 4.5 |
| EBITA | -238.9 | -258.3 | -185.1 | -188.0 | -105.3 | -48.9 | -40.1 | -31.1 |
| EBITA margin | -675.2% | -730.0% | -629.8% | -639.7% | -245.0% | -97.7% | -199.0% | -117.1% |
| Amortization of intangibles | 1.1 | | 1.1 | | 1.1 | 1.1 | 0.2 | |
| EBIT | -240.0 | -258.3 | -186.2 | -188.0 | -106.4 | -50.0 | -40.3 | -31.1 |
| EBIT margin | -678.3% | -730.0% | -633.5% | -639.7% | -247.5% | -99.8% | -200.0% | -117.1% |
| Pre-tax income | -249.1 | -249.1 | -187.1 | -187.1 | -108.5 | -52.0 | -41.8 | -31.1 |
| Income taxes | -0.4 | -0.4 | 0.0 | 0.0 | -0.4 | -4.4 | 0.0 | 0.0 |
| Tax rate | 0.2% | 0.2% | 0.0% | 0.0% | 0.3% | 8.4% | 0.0% | 0.0% |
| Net income | -248.7 | -248.7 | -187.1 | -187.1 | -108.2 | -47.7 | -48.8 | 0.0 |
| Net margin | -703.0% | -703.0% | -636.6% | -636.6% | -251.6% | -95.2% | -242.1% | -0.1% |
| |
| Diluted EPS | ($3.08) | ($3.08) | ($2.57) | ($2.57) | ($1.97) | ($17.19) | ($21.24) | ($20.25) |
| Shares outstanding (diluted) | 80.6 | 80.6 | 72.8 | 72.8 | 54.9 | 2.8 | 2.3 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|